NAACCR Item #3931: Serum Beta-2 Microglobulin Pretreatment Level
|Item #||Length||Source of Standard||Year Implemented||Version Implemented||Year Retired||Version Retired|
NAACCR XML: Tumor.serumBeta2MicroglobulinPretxLvl
Serum Beta-2 Microglobulin is a protein that is found on the surface of many cells and plentiful on the surface of white blood cells. Increased production or destruction of these cells causes Serum β2 (beta-2) Microglobulin level to increase. Elevated Serum β2 (beta-2) Microglobulin level is a prognostic factor for plasma cell myeloma.
Serum Beta-2 Microglobulin Pretreatment Level is a prognostic factor required in AJCC 8th edition, Chapter 82 Plasma Cell Myeloma and Plasma Cell Disorders, for staging of plasma cell myeloma.
|0||β2-microglobulin \<3.5 mg/L|
|1||β2-microglobulin =3.5 mg/L \<5.5 mg/L|
|2||β2-microglobulin =5.5 mg/L|
|5||Schema Discriminator 1: Plasma Cell Myeloma Terminology coded to 1 or 9|
|7||Test ordered, results not in chart|
|9||Not documented in medical record Serum Beta-2 Microglobulin Pretreatment Level not assessed or unknown if assessed|
Each Site-Specific Data Item (SSDI) applies only to selected primary sites, histologies, and years of diagnosis. Depending on applicability and standard-setter requirements, SSDIs may be left blank.